INTRODUCTION
============

Endothelial cells (ECs) line blood and lymphatic vessels, forming a semipermeable barrier between the blood and underlying tissue ([@B1], [@B2]). By sensing environmental changes, this cell layer regulates the transport of oxygen and essential nutrients to all organ systems in the human body ([@B37]; [@B53]; [@B48]). These continuous sensing capabilities are required to maintain vascular homeostasis and form the basis of many physiological and disease-related processes. Active participation of ECs in homeostasis is required not only to control the transport and diffusion of essential solutes, but also to carefully regulate many physiological processes, including inflammation, the constitutive and induced transendothelial migration (TEM) of immune cells, thrombosis, angiogenesis, and arteriogenesis ([@B33]; [@B25]; [@B46]; [@B19]).

The endothelium-dependent functions and characteristics thus play a central role in vascular stabilization, a process that depends in particular on intercellular contacts between adjacent ECs. Endothelial intercellular contacts are mediated by two types of junctional complexes: adherens junctions (AJs) and tight junctions (TJs). Whereas TJs regulate the diffusion of water, ions, and small molecules, the AJs control more diverse and complex functions in the endothelium, such as limiting edema, matrix exposure, and leukocyte TEM, by translating extracellular force into intracellular signaling and regulating the cross-talk between cell--cell and cell--matrix adhesions ([@B32]; [@B10]). AJs are mainly composed of the vascular endothelial cadherin protein (VE-cadherin), which is strictly required to establish EC--cell contacts and anchors AJs to the actin cytoskeleton via several adapter proteins ([@B26]; [@B9]; [@B14]). Because signaling toward the actin cytoskeleton dynamically controls the loss and gain in barrier function, VE-cadherin plays a major role in junctional stability and thereby vascular integrity.

There are a large number of receptor agonists, including growth factors, hormones, and bioactive lipids, that regulate endothelial barrier function in positive or negative ways ([@B32]). An important signaling molecule that, in most vessels, promotes VE-cadherin stabilization is sphingosine-1-phosphate (S1P; [@B27]). This bioactive sphingolipid, produced by ECs, erythrocytes, and, to some extent, activated platelets ([@B60]; [@B59]; [@B3]; [@B24]; [@B17]; [@B21]), is present in relatively high concentrations (100--600 nM) in plasma ([@B60], [@B61]; [@B8]; [@B5]). Extracellular S1P can bind to five different G-protein--coupled receptors (GPCRs), termed S1PR~1--5~, three of which (S1PR~1~, S1PR~2~, and S1PR~3~) are expressed in ECs. Resting, healthy ECs express mainly the S1PR~1~ and, to a lesser extent, the S1PR~2~ and S1PR~3~ as well ([@B11]). Activation of the S1PR~1~ induces vascular stabilization and enhanced barrier function, while both the S1PR~2~ and S1PR~3~ have been linked to disruption of the endothelium (reviewed in [@B58]). The balance in receptor subtype expression as well as plasma S1P concentration levels determines vascular integrity. Aberrant S1P plasma levels have been linked to multiple types of cancer, since binding to S1P receptors can promote tumor growth, angiogenesis, and metastasis ([@B40]). In addition, a shift in balance from dominant S1PR~1~ to S1PR~2~ signaling induces vascular permeability and inflammation ([@B44]; [@B62]).

As described above, the output of S1P-mediated endothelial barrier regulation is already determined at the level of the receptors. These receptors couple to heterotrimeric G-proteins, which reside at the intracellular side of the plasma membrane (PM) and consist of a Gα subunit and a Gβγ-dimer. In S1P-mediated barrier regulation, it is believed that three different Gα subunits are involved; Gα~i~, Gα~12/13~, and Gα~q~ ([@B38]). The S1PR~1~ is exclusively coupled to Gα~i~, and inhibition of this G-protein prevents increased barrier function of endothelial monolayers ([@B13]; [@B29]). The S1PR~2~ and S1PR~3~ couple to all three G-proteins, but how this receptor--G-protein coupling affects endothelial barrier regulation remains unexplored.

Downstream of heterotrimeric G-proteins, Rho guanine exchange factors (RhoGEFs) act to activate RhoGTPases, molecular switches that regulate cell morphology, polarity, adhesion, and migration through their differential control of F-actin dynamics ([@B22]; [@B42]). The RhoGTPases Rac1, Cdc42, and RhoA are the most well-studied ones, with Rac1 stimulating actin polymerization and lamellipodia-driven migration, Cdc42 promoting filopodia formation, and RhoA stimulating F-actin stress fiber formation and cell contraction while counteracting Rac1-induced cell spreading ([@B43]). By having strong effects on cell morphology and cytoskeletal dynamics, RhoGTPases are key regulators of endothelial barrier function. The contribution of Rac1, Cdc42, and RhoA in S1P-mediated barrier regulation was studied previously using biochemical approaches ([@B54]; [@B6]), providing evidence that all three are activated by S1P.

Because biochemical approaches 1) have only limited temporal resolution, 2) have no spatial resolution, and 3) are difficult to quantify, we analyzed S1P-induced signaling in detail using fluorescence resonance energy transfer (FRET) biosensors for RhoGTPases and for heterotrimeric G-proteins in monolayers of primary human ECs. We show direct, rapid S1P-mediated Gα~i~ and Gα~12/13~ activation, while Gα~q~ activation was lacking. In addition, FRET sensor measurements showed a sequential activation of Cdc42, RhoA, and Rac1 during S1P-mediated regulation of endothelial barrier function. The single-cell imaging approach reveals a detailed picture of signaling events in relation to cell morphology. Together, our results point to a model in which the balance between two opposing pathways determines EC morphology and monolayer integrity.

RESULTS
=======

S1P promotes endothelial barrier function
-----------------------------------------

Previous studies on S1P-mediated signaling in ECs have shown that extracellular S1P promotes vascular stabilization and increased barrier function ([@B27]; [@B13]). To understand this barrier-promoting effect in more detail, different approaches were used to examine S1P effects at the cellular level. First, S1P stimulation of semiconfluent human umbilical vein EC (HUVEC) cells was combined with immunofluorescence analysis. This allowed detection of morphological changes, which are difficult to detect in confluent endothelial monolayers. Unstimulated ECs showed mixed phenotypes in terms of F-actin distribution as reflected by contractile (stress fiber) and protruding (cortical actin-based) regions within a single cell ([Figure 1A](#F1){ref-type="fig"}). The cortical region of the cells showed enhanced phospho-paxillin levels, marking cortical focal adhesions (FAs), which correlated with cell spreading ([@B47]; [@B36]). After 2 min of S1P stimulation, ECs showed an extensive increase in cortical actin, together with more pronounced phospho-paxillin at focal contacts and FAs in the periphery of the cell. After 30 min of S1P stimulation, this cortical actin--phospho-paxillin region disappeared and phospho-paxillin was detected in more centrally distributed FAs ([Figure 1A](#F1){ref-type="fig"}).

![S1P promotes endothelial barrier function: analysis toward a single cell level. (A) ECs were grown to a semiconfluent monolayer, stimulated with S1P (500 nM), and stained for F-actin, phospho-paxillin, and VE-cadherin. Arrowheads highlight protruding areas. Scale bar = 25 μm. (B) ECs were grown to a monolayer on ECIS electrodes and stimulated with S1P at *t* = 0.3 h. Endothelial resistance (4000 Hz) was measured using the ECIS, normalized to the value at *t* = 0, and plotted versus time. (C) ECs, transiently transfected with mTq2, were grown to a monolayer. Local changes in the area of a single cell were measured before and after stimulation with S1P at *t* = 0:30 min. Graph displays a representative dataset of *n* = 9. (D) Corresponding image of the plot in C. Colors in the right image represent area change after S1P stimulation (look-up table panel on the right). Scale bar = 25 μm.](3371fig1){#F1}

In addition to the immunolabeling approach, we quantitatively analyzed the barrier-promoting effect of S1P using Electrical Cell-substrate Impedance Sensing (ECIS). S1P induced a fast increase in transendothelial electrical resistance of 20% ([Figure 1B](#F1){ref-type="fig"}). In addition, after ectopic expression of mTurquoise2 (mTq2, a CFP), we measured morphological changes of single cells in an endothelial monolayer to provide an outline of the cell area. Measuring the temporal changes in the cell area of single mTq2-expressing ECs in a monolayer demonstrated an average net 2.6% increase in cell area upon S1P addition ([Figure 1C](#F1){ref-type="fig"}). Detailed imaging of local changes in morphology, however, showed that some parts of the cells contracted while other parts spread in response to S1P ([Figure 1D](#F1){ref-type="fig"} and Supplemental Figure S1).

Collectively, these data show that the barrier-promoting effect of S1P on monolayers of ECs is a composite response composed of F-actin reorganization, FA redistribution, and localized spreading as well as contraction.

S1P activates different RhoGTPases that are linked to EC morphology changes
---------------------------------------------------------------------------

Our results demonstrated that S1P-mediated endothelial barrier promotion is not exclusively linked to cell spreading. To explore the molecular mechanisms behind this observation, we specifically focused on RhoGTPases. This group of proteins has been strongly linked to cell morphology regulation ([@B22]; [@B42]) and has been previously implicated in S1P-mediated endothelial barrier regulation.

Previous studies have reported detection of S1P-induced activation of the RhoGTPases Rac1, Cdc42, and RhoA in ECs using biochemical approaches ([@B54]; [@B6]). Here we set out to extend these observations by including the closely RhoA-related GTPases RhoB and RhoC in our analysis. Using a Cdc42/Rac interactive binding (CRIB) peptide--based pull-down assay, we found that Rac1 and Cdc42 showed immediate activation after stimulation with S1P (0.5 min; [Figure 2, A and B](#F2){ref-type="fig"}). More persistent Rac1 activation was also observed at 2, 5, 10 and 30 min of stimulation ([Figure 2A](#F2){ref-type="fig"}). Highest Cdc42 activation was observed at *t* = 2 min, with a decline at later time points (5, 10, and 30 min; [Figure 2B](#F2){ref-type="fig"}). In addition to Rac1 and Cdc42 activation, an increase in RhoA/B/C activation was observed after 0.5 min of S1P stimulation, and for RhoA/C, but not RhoB, activation decreased again at *t* = 2 min ([Figure 2, C--E](#F2){ref-type="fig"}).

![S1P activates different RhoGTPases, in line with EC morphology changes. (A, B) Rac1- and Cdc42-guanosine triphosphate (GTP) levels were increased after S1P (500 nM) stimulation, as measured by a CRIB peptide--based pull-down approach. Total protein levels of corresponding RhoGTPases were measured to control for equal loading. (C--E) RhoA-, RhoB-, and RhoC-GTP levels were increased after S1P (500 nM) stimulation, as measured by a rhotekin-RBD pull-down approach. Total protein levels of the corresponding RhoGTPases were measured to control for equal loading. (F) A rapamycin-dependent recruitment system was used to directly activate RhoGTPases. FRB, Lck-FRB-ECFP; F12, FKBP12-mCherry; GEF, either p63RhoGEF to induce RhoA activation or TIAM to induce Rac1 activation. (G) Application of the rapamycin-dependent system described in F. Rac1 activation via recruitment of TIAM induced an increase in cell area, while p63RhoGEF-mediated activation of Rho induced a decrease in cell area. Colors in the right image represent area changes (look-up table panel on the right). Scale bar = 20 μm.](3371fig2){#F2}

Because we observed parallel activation of the three major RhoGTPases upon S1P addition, we studied the connection between the activation of these proteins and specific EC morphological changes. To this end, we used rapamycin-induced membrane recruitment ([@B39]) of an ectopically expressed RhoGEF, which induces endogenous RhoGTPase activation upon translocation to the PM. Catalytic guanine exchange factor (GEF) domains of either p63RhoGEF (an activator of RhoA/B/C) or TIAM (an activator of Rac1) were fused to an FKBP12 domain and tagged with a fluorescent protein to examine their localization. In addition, we cotransfected Lck-FRB-ECFP, a membrane-anchored FKBP12-binding protein tagged with cyan fluorescent protein (CFP). Upon rapamycin addition, the FKBP12-GEF relocated to Lck-FRB-ECFP at the PM ([Figure 2F](#F2){ref-type="fig"} and Supplemental Movie S1). Recruitment of TIAM predominantly induced cell expansion (ΔArea: 22%; [Figure 2G](#F2){ref-type="fig"} and Supplemental Figure S2A), which is in line with the activation of Rac1. In contrast, recruitment of p63RhoGEF resulted in cell contraction (ΔArea: --12%), which is in line with the activation of RhoA/B/C GTPases ([Figure 2G](#F2){ref-type="fig"} and Supplemental Figure S2B). These effects on EC morphology were more pronounced as compared with S1P-mediated EC morphology changes (compare [Figure 1D](#F1){ref-type="fig"} and [Figure 2G](#F2){ref-type="fig"}), probably because relocation of constitutive active GEF proteins provides a stronger effect on RhoGTPases than activation of endogenous GEFs by a receptor-mediated signal.

In summary, we showed prominent S1P-mediated activation of different RhoGTPases, that is, Rac1, Cdc42, and RhoA/B/C. In addition, we could directly link changes in EC morphology to RhoGTPase activation by selective GEFs, namely Rac1-mediated spreading through expression of TIAM and Rho-mediated contraction through expression of p63 RhoGEF.

S1P induces spatiotemporal control of RhoGTPase activation
----------------------------------------------------------

Although we showed S1P-mediated activation of RhoGTPases, our biochemical approach lacks spatial information and has poor temporal resolution. In addition, quantification of these biochemical assays is challenging. To study S1P-mediated signaling with high spatiotemporal resolution, we used RhoGTPase FRET sensors. These unimolecular FRET sensors have been previously described ([@B28]; [@B50]; [@B51]; [@B23]; [@B41]) and can monitor fast yellow fluorescent protein (YFP)/CFP ratio differences in different cellular locations. An increase in YFP/CFP ratio corresponds to an increase in Rho­GTPase activation.

Sensor-expressing primary human ECs were grown to confluency and stimulated with S1P at *t* = 1:50 min after the initiation of imaging. Rac1, Cdc42, and RhoA/B/C FRET sensors all showed activation in response to S1P, with the majority of the signal localized to the periphery of the cells ([Figure 3A](#F3){ref-type="fig"} and Supplemental Figure S3). More detailed analysis of these FRET sensor experiments revealed striking temporal differences in RhoGTPase activation that could not be detected on Western blot (compare [Figure 2, A--E](#F2){ref-type="fig"}, and [Figure 3, A and B](#F3){ref-type="fig"}). After S1P addition, a fast decrease (reaching a minimum 1:00 min after S1P addition) in Rac1 activation was observed, followed by an increase that reached its maximum (YFP/CFP~max~) 3:50 min after addition of S1P. Of note, measuring 32 single Rac1 sensor-expressing cells revealed two different populations of responders (Supplemental Figure S4). In addition to a population of cells (18 out of 32) with similar kinetics as the overall mean (*n* = 18), a second population showed a comparable initial decrease in Rac1 activation but never reached a YFP/CFP~max~ above baseline (*n* = 14). In contrast to Rac1, maximal FRET changes were detected at earlier time points for Cdc42 (0:40 min after addition) and RhoA (0:30 min after addition). In addition, a second Cdc42 activation peak at 3:00 min after S1P addition was detected. Zooming in on the first 7 min of the FRET sensor analyses of [Figure 3B](#F3){ref-type="fig"} highlights the notion that the fast peak in Cdc42 and RhoA activation coincides with the initial reduction in Rac1 activation (first dashed line in [Figure 3C](#F3){ref-type="fig"}). In addition, the second Cdc42 activation peak coincides with the delayed increase in Rac1 activation ([Figure 3C](#F3){ref-type="fig"}, second dashed line).

![S1P induces spatiotemporal control of Rac1, Cdc42, and RhoA activation. (A) Ratiometric images of ECs that were transfected with the Rac1, Cdc42, or RhoA FRET sensor and stimulated with S1P (500 nM) at *t* = 1 min, 50 s. Warm colors represent high activation (high YFP/CFP ratios) and correspond to the emission ratios (ERs) on the right. Scale bar = 15 μm for Rac1 and 25 μm for Cdc42 and RhoA images. (B) Normalized mean YFP/CFP ratio traces (±SEM) for Rac1 (*n* = 32), Cdc42 (*n* = 19), and RhoA (*n* = 12) FRET sensor-expressing ECs before and after stimulation with S1P. (C) Zoom of normalized mean YFP/CFP ratio traces (±SEM) corresponding to the first 7 min of the traces in B. Dashed lines highlight maximal and minimal changes in YFP/CFP ratios for the different GTPases (see section *S1P induces spatiotemporal control of RhoGTPase activation*).](3371fig3){#F3}

Overall these data show that S1P triggers differential spatiotemporal activation of Rac1, Cdc42, and RhoA. The time course of S1P-induced (in)activation of Rac1 is a mirror image of the S1P-induced transient activation of RhoA. In contrast to Rac1, Cdc42 is activated at 0:40--3 min with similar kinetics as RhoA. However, while RhoA is inactivated after 2--5 min of stimulation, Cdc42 shows more persistent activation. Thus, all three GTPases show distinct (in)activation profiles in response to S1P.

S1P activates Gα~i~ and Gα~13~ but not Gα~q~
--------------------------------------------

The FRET sensor data revealed a rapid (in)activation of the three major RhoGTPases. To understand how the regulation of RhoGTPase activity is orchestrated, we examined receptor-proximal events. S1P binds various GPCRs, initiating intracellular signaling events via activation of different heterotrimeric G-proteins. To examine which of these G-proteins are activated by S1P, we used dedicated FRET-based biosensors that have recently been developed in our lab ([@B15]; [@B52]).

The heterotrimeric G-protein sensors use a Gα subunit tagged with a donor and a Gγ2 subunit tagged with an acceptor. The intact complex in resting cells shows FRET, which is lost upon activation. This means that a decrease in YFP/CFP ratio corresponds to an increase in G-protein activation ([Figure 4A](#F4){ref-type="fig"}, representing a schematic on the working mechanism of these sensors). We recently showed that S1P strongly activates the Gα~i~ protein in ECs ([@B52]). However, according to published literature, both Gα~13~ and Gα~q~ also play a role in S1P-mediated signaling in ECs ([@B38]). To measure activation of Gα~13~, we made use of a new sensor (M.M. and J.G., unpublished data) that comprised a Gα~13~ subunit tagged with mTq2 as the donor and a YFP-tagged Gγ2 subunit as the acceptor. First, we characterized the Gα~13~ sensor by stimulating ECs with thrombin, a well-known Gα~13~ activator ([@B35]; [@B4]; [@B31]). Stimulation of Gα~13~ FRET sensor-­expressing ECs induced a FRET ratio change distributed throughout the entire cell, reaching a YFP/CFP~max~ (--17%) 25 s after thrombin stimulation ([Figure 4](#F4){ref-type="fig"}B). The observation that the new sensor responds to stimulation of an endogenous GPCR suggests that the Gα~13~ FRET sensor can be used as a robust and sensitive read-out of Gα~13~ activation.

![S1P induces Gα~13~ but not Gα~q~ activation. (A) G-protein FRET sensor design, consisting of (from N- to C-terminus) Gβ-2A-YFP-Gγ~2~-IRES-Gα-mTq2 ([@B15]; [@B52]). (B) Normalized mean YFP/CFP ratio traces (±SEM) of Gα~13~ FRET sensor-expressing ECs (*n* = 6) stimulated with thrombin (1 U/ml) at *t* = 55 s, including ratiometric images of the indicated time points (similar in C--E). (C) Normalized mean YFP/CFP ratio traces (±SEM) of Gα~13~ FRET sensor-expressing ECs (*n* = 14) stimulated with S1P (500 nM) at *t* = 55 s. (D) Normalized mean YFP/CFP ratio traces (±SEM) of Gα~q~ FRET sensor-expressing ECs (*n* = 12) stimulated with S1P (500 nM) at *t* = 55 s. (E) Normalized mean YFP/CFP ratio traces (±SEM) of Gα~q~ FRET sensor-expressing ECs (*n* = 10) stimulated with histamine (100 μM) at *t* = 55 s. Blue colors represent high activation (low YFP/CFP ratios) and correspond to the emission ratios (ERs) on the right. Scale bar = 20 μm.](3371fig4){#F4}

Compared with thrombin activation, similar Gα~13~ spatiotemporal activation kinetics were detected after stimulation with S1P, reaching YFP/CFP~max~ (--11%) 20 s after stimulation ([Figure 4C](#F4){ref-type="fig"}). Surprisingly, S1P stimulation did not induce Gα~q~ activation in Gα~q~ sensor-expressing cells ([Figure 4D](#F4){ref-type="fig"}). In contrast, the well-known Gα~q~ activator histamine showed fast and robust Gα~q~ activation (--17% YFP/CFP~max~ 5 s after histamine stimulation; [Figure 4E](#F4){ref-type="fig"}). Taken together, these G-protein FRET sensor experiments reveal that, in addition to Gα~i~, the G-protein Gα~13~ but not Gα~q~ is activated by S1P in ECs.

The S1P~1~ receptor exclusively signals toward Gα~i~, Rac1, and Cdc42
---------------------------------------------------------------------

To study the link between heterotrimeric G-protein and RhoGTPase signaling, we wanted to use a method to activate only Gα~i~-mediated signaling. The compound SEW2871 is reported as a specific agonist for the S1P~1~ receptor and activator of Gα~i~. Like S1P, SEW2871 stimulation resulted in an increase in transendothelial electrical resistance as measured by ECIS ([Figure 5A](#F5){ref-type="fig"}). In addition, SEW2871 showed robust Gα~i~ activation within 1 min of stimulation ([Figure 5B](#F5){ref-type="fig"}). No SEW2871-induced changes in Gα~13~ activation could be detected ([Figure 5C](#F5){ref-type="fig"}).

![SEW2871 promotes endothelial barrier function and activates Gα~i~, Rac1, and Cdc42. (A) ECs were grown to a monolayer on ECIS electrodes and stimulated with SEW2871 (5 μM) at *t* = 0.3 h after start of the analysis. Endothelial resistance (4000 Hz) was measured using the ECIS. (B) Normalized mean YFP/CFP ratio traces (±SEM) of Gα~i~ FRET sensor-expressing ECs (*n* = 14) stimulated with SEW2871 (5 μM) at *t* = 55 s. (C) Normalized mean YFP/CFP ratio traces (±SEM) of Gα~13~ FRET sensor-expressing ECs (*n* = 16) stimulated with SEW2871 (5 μM) at *t* = 55 s. (D) Normalized mean YFP/CFP ratio traces (±SEM) for Rac1 (*n* = 16), Cdc42 (*n* = 8), and RhoA (*n* = 6) FRET sensor-expressing ECs before and after stimulation with SEW2871 (5 μM) at *t* = 1 min, 50 s. (E) Zoom of normalized mean YFP/CFP ratio traces (±SEM) corresponding to the first 7 min of D. Dashed lines highlight maximal YFP/CFP ratio changes of Rac1 and Cdc42.](3371fig5){#F5}

Because SEW2871 appeared to exclusively signal toward Gα~i~, we next explored its signaling toward the GTPases Rac1, Cdc42, and RhoA. After addition of SEW2871, increases in Rac1 and Cdc42 activation were observed, while RhoA sensor-expressing ECs did not show a change in FRET ([Figure 5D](#F5){ref-type="fig"}). In contrast to S1P-induced Rac1 activation, activation of Rac1 by SEW2871 was not preceded by Rac1 inactivation, indicating that the rapid inactivation of Rac1 by S1P is mediated by RhoA. In addition, comparing the activation of Rac1 and Cdc42 showed Cdc42 activation at 1--3 min after stimulation, whereas Rac1 activation is maximal at 4--5 min after stimulation, showing similar dynamics as the S1P-mediated activation (compare [Figure 5, D and E](#F5){ref-type="fig"}, with [Figure 3, B and C](#F3){ref-type="fig"}). In summary, the endothelial barrier-promoting compound SEW2871 acts through Gα~i~, Rac1, and Cdc42 but does not activate RhoA.

Gα~i~ signaling pathways are required for S1P-mediated endothelial barrier stimulation
--------------------------------------------------------------------------------------

The responses of ECs to SEW2871 suggest that Gα~i~ determines S1P signaling toward Rac1 and Cdc42. We therefore explored whether Rac1 and/or Cdc42 activation exclusively depends on Gα~i~ and to what extent this regulates S1P-mediated barrier regulation in ECs. To block signaling through Gα~i~, we used pertussis toxin (PTX). This toxin selectively ADP-ribosylates Gα~i~, abolishing its activation. ECs, transiently expressing the Rac1, Cdc42, or RhoA sensor, were treated with PTX for at least 18 h before stimulation with S1P. PTX-treated ECs lacked both Rac1 and Cdc42 activation after stimulation with S1P, while the fast Rac1 inactivation remained detectable ([Figure 6, A and B](#F6){ref-type="fig"}). RhoA sensor-expressing and PTX-pretreated ECs still showed prominent S1P-induced activation after pretreatment with PTX ([Figure 6C](#F6){ref-type="fig"}), and a prolonged response was observed compared with untreated ECs (compare B and C in [Figure 3](#F3){ref-type="fig"}). This suggests that the RhoA inactivation, observed in untreated cells 1--4 min after S1P, is mediated by a Rac1/Cdc42-dependent signaling pathway.

![Gα~i~ signaling is required for S1P-mediated Rac1/Cdc42 activation and endothelial barrier promotion. (A--C) Normalized mean YFP/CFP ratio traces (±SEM) for Rac1 (*n* = 12), Cdc42 (*n* = 9), and RhoA (*n* = 13) FRET sensor-expressing ECs (pretreated with 100 ng/ml PTX) before and after stimulation with S1P (500 nM) at *t* = 1:50. (D) ECs were grown to a monolayer on ECIS electrodes, pretreated with water or PTX dissolved in water (100 ng/ml), and stimulated with S1P (500 nM) at *t* = 50 min. Endothelial resistance (4000 Hz) was measured using the ECIS. (E) EC were grown to a semiconfluent monolayer, pretreated with PTX as above, stimulated with S1P (500 nM), and stained for F-actin, phospho-paxillin, and VE-cadherin. Scale bar = 25 μm.](3371fig6){#F6}

As for the endothelial barrier function, the effect of Gα~i~ inhibition was studied by using the ECIS. Control and PTX-treated endothelial monolayers were stimulated with S1P, where PTX-treated cells started at a slightly lower baseline level (Supplemental Figure S5). Control cells showed a barrier-promoting response similar to that described above ([Figure 1B](#F1){ref-type="fig"}). Strikingly, a substantial loss of endothelial barrier integrity was observed upon S1P stimulation of PTX-treated cells ([Figure 6D](#F6){ref-type="fig"}). The observed decrease in barrier function returned to baseline with the same kinetics as the control ([Figure 6D](#F6){ref-type="fig"}). This reversed effect on the endothelial barrier was also observed in PTX-treated ECs analyzed by immunostaining. Unstimulated ECs in a semiconfluent cell layer, and treated with PTX, predominantly showed a contractile phenotype with disruption of the junctional VE-cadherin complex ([Figure 6E](#F6){ref-type="fig"}). In contrast to what we have seen in [Figure 1A](#F1){ref-type="fig"}, S1P stimulation did not result in increased cell protrusion (compare [Figure 1A](#F1){ref-type="fig"} and [Figure 6E](#F6){ref-type="fig"}). Moreover, increased levels of stress fibers and enlarged phospho-paxillin--positive FAs were observed after stimulation with S1P, indicating that a contractility-regulating (i.e., RhoA-driven) pathway becomes dominant over a cell-spreading (i.e., Cdc42/Rac1-driven) pathway in PTX-treated ECs.

Collectively, these data suggest that Gα~i~ is specifically linked to Rac1 and Cdc42 activation and that this pathway is dominant in S1P-stimulated ECs, promoting endothelial barrier function.

Specific Gα~13~ inhibition affects Rac1 and RhoA but not Cdc42 signaling
------------------------------------------------------------------------

Although Gα~i~ is required for Rac1/Cdc42 activation and for the S1P-induced increase in endothelial barrier function, the role of Gα~13~ signaling in S1P signaling is unexplored. Because no pharmacological inhibitors have been reported for Gα~13~, a different strategy was required to specifically inhibit this type of G-protein. Therefore, we used p115RhoGEF, a specific RhoGEF that becomes activated in Gα~13~-mediated signaling pathways ([@B18]). In addition to its GEF activity toward RhoGTPases, p115RhoGEF acts as a GTPase activating protein (GAP) for Gα~13~ proteins via its so-called regulator of G-protein signaling (RGS) domain ([@B49]). p115-RGS accelerates intrinsic Gα~13~ GTPase activity, thereby selectively blocking the activation of Gα~13~-coupled GPCRs.

To use the p115-RGS domain to inhibit Gα~13~-mediated signaling, p115-RGS was cloned from full-length p115RhoGEF and tagged with the mCherry-fluorescent protein. We created three different versions of tagged p115-RGS: C-terminal tagged (p115-RGS-mCherry), N-terminal tagged (mCherry-p115-RGS), and membrane-linked, N-terminal tagged (Lck-mCherry-p115-RGS). To test the efficiency of Gα~13~ inactivation of these constructs, RhoA sensor-expressing HeLa cells were cotransfected with Gα~13~-QL (a constitutively active Gα~13~ mutant) and/or the different p115-RGS constructs. Compared with control cells, overexpression of Gα~13~-QL induced an increase in RhoA activation (Supplemental Figure S6). Although all three p115-RGS constructs diminished this Gα~13~-QL--mediated increase in RhoA activation, Lck-mCherry-p115-RGS was the most efficient (Supplemental Figure S6).

Next, the effect of Gα~13~ inhibition was studied on S1P-mediated RhoGTPase activation. In Rac1 sensor-expressing ECs, cotransfection with either Lck-mCherry or Lck-mCherry-p115-RGS showed a similar increase in S1P-induced Rac1 activation. Intriguingly, Lck-mCherry-p115-RGS cotransfected cells showed a less-pronounced Rac1 inactivation drop at 3--5 min as well as a higher maximal FRET ratio. In contrast, Lck-mCherry-p115-RGS almost completely inhibited S1P-induced RhoA activation, whereas no effect on Cdc42 activation was observed ([Figure 7, A and B](#F7){ref-type="fig"})

![Gα~13~ inhibition enhances S1P-induced Rac1 activation and blocks RhoA activation. (A) Normalized mean YFP/CFP ratio traces (±SEM) for Rac1, Cdc42, and RhoA FRET sensor-expressing ECs before and after stimulation with S1P at *t* = 1 min, 50 s. FRET sensor--positive ECs coexpress either Lck-mCherry (control) (Rac1, *n* = 20; Cdc42, *n* = 21; RhoA, *n* = 14) or Lck-RGS-mCherry (RGS) (Rac1, *n* = 27; Cdc42, *n* = 22; RhoA, *n* = 14). (B) Enlargement of normalized mean YFP/CFP ratio traces (±SEM) corresponding to the first 7 min of A. Dashed lines highlight maximal and minimal YFP/CFP ratio changes. Note the increased Rac1 activation at ∼7 min and the inhibition of RhoA activation upon coexpression of the RGS domain. (C) Model describing S1P-mediated signaling pathways in ECs. Balancing G-protein and RhoGTPase signaling results in S1P-induced cell spreading, which dominates over the limited RhoA activation and consequent contraction.](3371fig7){#F7}

Taken together, these experiments demonstrated that membrane-linked p115-RGS efficiently inhibits Gα~13~-mediated signaling and S1P-induced activation of RhoA. This inhibition of RhoA activation was also reflected in increased and more sustained Rac1 activation, while Cdc42 remained unaffected. These data, in combination with the findings presented in [Figures 3](#F3){ref-type="fig"} -- [6](#F6){ref-type="fig"}, further support the notion that in ECs, Rac1 and RhoA mutually inhibit each other, whereas Cdc42 is activated by a Cdc42-selective GEF and is insensitive to RhoA-mediated inhibitory cross-talk ([Figure 7C](#F7){ref-type="fig"}).

DISCUSSION
==========

This study reveals that the integrated activity of RhoA, Rac, and Cdc42 determines the effect of S1P on EC morphology and endothelial barrier function. We have uncovered a link between the activity of specific heterotrimeric G-proteins and RhoGTPases in ECs. Furthermore, we link the activity of individual RhoGTPases to EC morphology. Our results provide evidence for a model ([Figure 7C](#F7){ref-type="fig"}) in which S1P activates two pathways in ECs that have opposing effects on cell morphology. On the one hand, the S1P~1~ receptor couples to Gα~i~ and consequently activates both Rac1 and Cdc42, albeit with different kinetics and most likely through different GEFs. On the other hand, RhoA is activated, most likely via the S1P~2~ receptors that signal toward Gα~13~. The balance between these pathways is determined at the level of the receptors or the heterotrimeric G-proteins and determines the effect of S1P on cell shape and ultimately barrier function. Our study implies that the relative expression of S1P receptor isoforms and heterotrimeric G-proteins determines the signaling outcome. Under native conditions, the Rac1/Cdc42-based signaling dominates, leading to a net increase in cell spreading and increased barrier function in endothelial monolayers. However, under specific (patho)physiological conditions, altered receptor levels may change the signaling outcome.

Previous studies on S1P signaling in ECs, mainly focused on barrier regulation of endothelial monolayers, showed that S1P stimulation promotes vascular stability. Intriguingly, several biochemical experiments have revealed S1P-mediated activation of the most well-studied GTPases Rac1, Cdc42, and RhoA in ECs ([@B54]; [@B6]). Both the barrier-promoting effect of S1P and the activation of the three types of Rho GTPases by pull-down assay on cell extracts were corroborated in this study.

The barrier-promoting effect was measured using ECIS. However, ECIS lacks spatial information and details on the molecular mechanisms underlying morphological changes. Our biochemical approach that measures active Rho GTPases, showing S1P-dependent activation of different RhoGTPases, lacks spatial information, has low temporal resolution, and is difficult to quantify with some precision. Furthermore, both assays require large cell numbers, thereby completely lacking detection of cell-to-cell variation.

To circumvent the limitations of the aforementioned approaches, we undertook detailed analysis of RhoGTPase activation in space and time by performing single-cell FRET measurements. By using recently developed and validated single-chain RhoGTPase FRET sensors ([@B28]; [@B50]; [@B51]; [@B23]; [@B41]), we visualized robust activation and differences in activation profiles between Rac1, Cdc42, and RhoA/B/C. Here, we show that upon S1P stimulation, Rac1 is initially inactivated and that this inactivation is paralleled by increase in RhoA activation, suggesting that RhoA suppresses Rac1 activity (in line with previous studies in a different context, which are reviewed in [@B7]). The observed RhoA activation can explain the observed local contraction ([Figure 1D](#F1){ref-type="fig"}). In contrast to Rac1 and parallel to RhoA, Ccd42 shows a rapid activation, which also correlated well with the fast barrier-protective effect of S1P, which was detected using ECIS. The observation that the earliest response to S1P, that is, a rapid increase in barrier function, is paralleled by activation of Cdc42 and RhoA and inhibition of Rac1 suggests that Cdc42 is the most relevant GTPase mediating this initial stabilizing effect on cell--cell junctions, overruling RhoA-mediated contractility. Based on the distinct Rac1 and Cdc42 activation profiles and our findings using the S1PR~1~ agonist SEW2871, we hypothesize that different GEFs and GAPs are involved in these responses: a Cdc42-specific GEF and RhoA-dependent, Rac1-specific GAP during the initial activation at 1--3 min and one or more Cdc42/Rac1 GEF(s), which ensure activation of both GTPases at ∼4--7 min, in conjunction with a RhoAGAP, which downregulates RhoA activation. Future research is warranted to define how a single S1P receptor can activate different GEFs sequentially, an effect possibly related to receptor dimerization, feedback loops, or internalization, inducing a time delay in downstream signaling.

The activities of Rac1, Cdc42, and Rho GTPases in S1P signaling are orchestrated by upstream events. Three different GPCRs (S1PR~1~, S1PR~2~, and S1PR~3~) initiate S1P signaling in ECs and have been hypothesized to couple to different heterotrimeric G-proteins, Gα~i~, Gα~13~, and Gα~q~. For the first time, to our knowledge, we have been able to directly measure, using a newly developed Gα~i~ FRET sensor ([@B52]), S1P-induced Gα~i~ activation in single human ECs. A novel FRET-based sensor based on the same design (M.M. and J.G., unpublished data) was sensitive enough to detect thrombin-mediated activation of Gα~13~ in ECs. By using FRET sensors for Gα~13~ or Gα~q~, we observed that Gα~13~ but not Gα~q~ is activated by S1P. Together, our data show that S1P-mediated barrier regulation in human endothelium is predominantly controlled by Gα~i~ and Gα~13~. The specific S1PR~1~ agonist SEW2871 furthermore shows exclusive coupling to Gα~i~, resulting in activation of Rac1 and Cdc42 but not RhoA. We observed neither initial Rac1 inactivation nor RhoA activation in response to this S1PR~1~-Gα~i~ activation, underlining the antagonistic properties of RhoA toward Rac1 in the early phase after S1P activation.

Inhibition of Gα~i~ by PTX abolished S1P-induced Rac1/Cdc42 activation. This indicates that Rac1/Cdc42 activation is not only mediated but also restricted to Gα~i~ signaling. The lack of Gα~i~-Rac1/Cdc42 signaling furthermore results in dominant RhoA signaling, as shown by prolonged RhoA FRET signals showing a lack of RhoA inactivation. Gα~i~ inhibition has a striking effect on signaling outcome, completely reversing the S1P responses in the ECIS (i.e., loss rather than gain of barrier function). At a cellular level, the inhibition of Gα~i~ results in S1P-induced cell contraction, explaining the loss of barrier function observed in ECIS. Inhibition of Gα~i~ thus shifts S1P signaling toward an output dominated by RhoA, suggesting that S1P-mediated barrier regulation is determined at the level of the heterotrimeric G-proteins and their activating receptors. Whereas Gα~i~ regulates sequential activation of Cdc42 and Rac1, Gα~13~ exclusively and rapidly activates Rho signaling and consequent cell contraction.

GPCRs may activate multiple different heterotrimeric G-proteins ([@B56]), either via a single GPCR or via multiple GPCRs that activate different heterotrimeric G-proteins but react to the same ligand, as is the case for S1P receptors. Because we demonstrate that the output of such networks can be explained only by observing multiple parameters, our results have important implications for understanding signaling networks activated by GPCRs. Ideally, multiple events are measured at the same time by multiparameter imaging ([@B55]), and this remains a challenge for the future. The FRET-based sensors used in this study for heterotrimeric G-proteins and RhoGTPases have proven to be valuable tools for dissecting the complexity of signaling networks in primary cells.

The effects of S1P are generally assumed to promote endothelial integrity and vascular stability. However, it is important to note that the outcome of S1P-induced signaling may divert from this generic response: vascular beds may affect the outcome of this signaling, and signaling outcomes may even differ among different sections of the same blood vessel ([@B16]; [@B12]). Moreover, S1P in plasma is bound to carrier proteins, and differential effects of high-density lipoprotein--bound S1P versus albumin-bound S1P have been reported ([@B57]; [@B12]). Also, variations in S1P receptor coding sequences ([@B34]) or receptor expression levels in health and disease ([@B30]) may account for different outcomes of S1P-induced signaling. On top of the aforementioned layers of regulation, our results imply that the precise balance of components immediately downstream of the S1P receptor, that is, heterotrimeric G-proteins, Rho GEFs, and GAPs, provide a fine-tuning mechanism for the spatiotemporal activation patterns of the Rho GTPases and ultimately determine effects on vascular stability.

In summary, our study unravels detailed molecular characteristics of S1P-mediated signaling pathways that regulate endothelial barrier function. Using FRET-based biosensors, we performed high-resolution spatiotemporal single-cell analysis of G-protein and RhoGTPase signaling in primary human endothelium and uncovered sequential RhoGTPase activation and partial cross-talk between RhoA and Rac1 but not Cdc42. Finally, this work emphasizes the need to study S1P-based signaling pathways that regulate vascular integrity in different tissues and vascular beds.

MATERIAL AND METHODS
====================

Plasmids
--------

Full-length p115RhoGEF (a kind gift of P. Sternweis) was used to amplify the p115RhoGEF-RGS domain (amino acids 1--252) by PCR amplification, using forward primer 5′-GAGATC[AGATCT]{.ul}ATGGAAGACTTCGCCCGAG-3′ and either reverse primer \#1 GAGATC[GAATTC]{.ul}TTAGTTCCCCATCACCTTTTTC-3′ or reverse primer \#2 GAGATC[GAATTC]{.ul}TGTTCCCCATCACCTTTTTCCG-3′. After amplification, the PCR fragments and vectors were cut with *Bgl*II and *Eco*RI (restriction sites are underlined in the primer sequence). Next, PCR fragments were ligated into C1-mCherry, N1-mCherry, or C1-Lck-mCherry to generate C1-mCherry-RGS, N1-RGS-mCherry, and C1-Lck-mCherry-RGS. The translocatable, catalytic domain of TIAM was obtained from Addgene (plasmid \#20154) and described by [@B20], and translocatable catalytic p63RhoGEF was described by [@B51]. The FRET biosensors for Gα~i~ ([@B52]), Gα~q~ ([@B15]), RhoA ([@B28]; [@B51]), RhoB/RhoC ([@B41]), Rac1 ([@B50]), and Cdc42 ([@B23]) were as described in the cited references. A sensor for Gα~13~ was constructed by inserting mTq2 into the αB αΒ1 loop between the αB and αΒ1 helices. The tagged Gα~13~ subunit was coexpressed with a YFP-tagged Gγ2 subunit ([@B15]). To ascertain robust coexpression, the tagged subunits were expressed from a single plasmid as recently reported for the Gα~i~ sensor ([@B52]). The engineering and full characterization will be described elsewhere (M.M. and J.G., unpublished data).

HUVEC cell culture and transfection
-----------------------------------

Primary HUVECs were acquired from Lonza (Verviers, Belgium) and seeded on culture flasks coated with fibronectin (FN). HUVECs were grown in EGM-2 medium, supplemented with SingleQuots (Lonza), and transfected at passage \#4 or \#5 with a Neon transfection system (MPK5000, Invitrogen) and Neon transfection kit (Invitrogen). Per transfection, 2 μg plasmid DNA was used, and a single pulse was generated at 1300 V for 30 ms. After microporation, HUVECs were grown to a monolayer on FN-coated glass coverslips.

HeLa cell culture and transfection
----------------------------------

HeLa cells were acquired from American Type Culture Collection (Manassas, VA). Cells were cultured in DMEM (Invitrogen, Bleiswijk, Netherlands), supplemented with GlutaMAX, 10% FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml). HeLa cells were seeded on 24-mm glass coverslips (Menzel-Gläser, Braunschweig, Germany) and transfected with 1 μg plasmid DNA, 4 μg polyethylamine (PEI 25,000) in water (Polysciences), and 100 μl OptiMeM (Life Technologies, Bleiswijk, Netherlands).

Reagents
--------

S1P was from Avanti Polar Lipids, rapamycin was from LC Laboratories (Woburn, MA), thrombin (HCT-0020) was from Haematologin Technologies, histamine (H7125) was from Sigma-Aldrich, SEW2871 (10006440) was from Cayman Chemical, and PTX (PHZ1174) was from Thermo Fisher. All compounds were prepared per the manufacturers' instructions.

Antibodies
----------

Actin-stain 555 Phalloidin (Cytoskeleton), monoclonal antibody (mAb) mouse anti--VE-cadherin/CD144 AF647 (BD PharMingen), polyclonal antibody (pAb) rabbit anti--phospho-paxillin (PY118), and secondary antibody anti-rabbit AF488 were used for immunofluorescence.

For immunoblotting, mAb mouse anti-Rac1 and --anti-Cdc42 were purchased from BD Transduction Laboratories. mAb rabbit anti-RhoA and --anti-RhoC were from Cell Signaling. pAb rabbit anti-RhoB was from Santa-Cruz Biotechnology, and mAb mouse anti-actin was purchased from Sigma. Secondary antibody, HRP-labeled goat anti-mouse, and swine anti-rabbit were obtained from Dako.

ECIS
----

ECIS (Applied Biophysics, New York) electrode arrays (8W10E) were preincubated with 10 mM [l]{.smallcaps}-cysteine (Sigma) for 5 min at 37°C and coated with FN (10 μg/ml, 0.9% NaCl \[Sigma\]) for ≥1 h at 37°C. After coating, HUVECs were seeded (150,000 cells per well) and grown to confluence. The electrical resistance, as a measure of endothelial barrier function, was recorded at a frequency of 4000 Hz at 37°C and 5% CO~2~.

CRIB-based Rac1/Cdc42 pull-down assays
--------------------------------------

HUVECs were grown to a monolayer, stimulated as described, and washed with ice-cold phosphate-buffered saline (PBS; 1 mM CaCl~2~, 0.5 mM MgCl~2~). Next, cells were lysed for 5 min on ice in lysis buffer containing 50 mM Tris (pH 7.4), 0.5 mM MgCl~2~, 500 mM NaCl, 1% (vol/vol) Triton X-100, 0.5% (wt/vol) deoxycholic acid, and 0.1% (wt/vol) SDS supplemented with protease inhibitors (Roche). Lysed cells were cleared by centrifuging for 5 min at 14000 × *g* and incubated with biotinylated Pak1-CRIB peptide coupled to streptavidin beads ([@B45]). After ≥30 min of incubation at 4°C, beads were washed five times in 50 mM Tris (pH 7.4), 0.5 mM MgCl~2~, 150 mM NaCl, and 1% (vol/vol) Triton X-100 and eluted in SDS-sample buffer containing 4% β-mercaptoethanol. Samples were analyzed by Western blot using either anti-Rac or anti-Cdc42 antibodies.

Rhotekin-Rho binding domain (RBD) pull-down assay
-------------------------------------------------

HUVECs were grown to a monolayer, stimulated as described, and washed with ice-cold PBS (1 mM CaCl~2~, 0.5 mM MgCl~2~). Next, cells were lysed for 5 min on ice in 25 mM Tris-HCl (pH 7.2), 150 mM NaCl, 10 mM MgCl~2~, 1% NP-40, and 5% glycerol supplemented with protease inhibitors (Roche). Lysed cells were cleared by centrifuging for 5 min at 14,000 × *g* and incubated with bacterially produced glutathione *S*-transferase rhotekin-RBD beads ([@B45]). After ≥30 min of incubation at 4°C, beads were washed five times in the abovementioned lysis buffer and boiled in SDS-sample buffer containing 4% β-mercaptoethanol. Samples were analyzed on Western blot by using anti-RhoA, anti-RhoB, or anti-RhoC antibodies.

Confocal imaging
----------------

HUVECs were seeded on FN-coated 14-mm glass coverslips and grown to a semiconfluent monolayer. After stimulation, cells were washed with PBS (1 mM CaCl~2~ and 0.5 mM MgCl~2~) and fixed for 5 min in PBS (1 mM CaCl~2~, 0.5 mM MgCl~2~) containing 4% formaldehyde. Next, cells were permeabilized for 5 min in PBS containing 0.5% Triton X-100, followed by 20-min incubation in 0.5% PBS-bovine serum albumin (BSA) blocking buffer. Subsequently, cells were incubated for 1 h with primary antibodies and 45 min with secondary or directly labeled antibodies, all of them dissolved in 0.5% PBS-BSA. Fluorescent images were collected on a Zeiss LSM510/Meta confocal laser-scanning microscope equipped with a 63× oil-immersion objective (numerical aperture \[NA\] 1.40) and Zeiss/Zen 2011 software.

Live HUVEC FRET measurements
----------------------------

Glass coverslips, containing transfected HUVECs, were placed in an Attofluor cell chamber (Thermo Scientific) 16--20 h after electroporation. Cells were stimulated as indicated, and live-cell FRET images were collected on a widefield Zeiss Observer Z1 microscope equipped with a 40× oil-immersion objective (NA 1.3), an HXP 120-V excitation light source, and Zeiss/Zen 2011 software. CFP was excited using a FRET filter cube with Exciter ET 436/20 and a 455 dichroic longpass (DCLP) mirror (Chroma, Bellows Falls, VT). Emission light was directed to a second dichroic mirror (510 DSCP; Chroma, Bellows Falls, VT) and simultaneously captured with two individual Hamamatsu ORCA-R2 digital charge-coupled device cameras. CFP emission (455--510) was captured on the first camera via an ET 480/40-nm emission filter (Chroma, Bellows Falls, VT). Emission wavelengths of \>510 (YFP) were captured on the second camera by using an ET 540/40-nm emission filter (Ludl Electronics Products, Hawthorne, NY). FRET image and ratio analysis was performed in ImageJ according to [@B50] and [@B41].

Static HeLa cell FRET measurements
----------------------------------

HeLa cells were transfected as indicated, and glass coverslips were placed in Attofluor cell chambers 16--20 h after transfection. Live-cell FRET images were collected on a widefield Axiovert 200M microscope (Carl Zeiss GmbH) equipped with a Plan-Neofluor 40× oil-immersion objective (NA 1.3), a xenon arc lamp with monochromator (Cairn Research, Faversham, Kent, UK), and Metamorph 6.1 software. Images were acquired using a cooled charged-coupled device camera (Coolsnap HQ, Roper Scientific, Tucson, AZ). CFP was excited at 420 nm (slit width, 30 nm) via a 455 DCLP dichroic mirror, and emission light was directed to a 470/30-nm emission filter. Using a rotating emission filter wheel, YFP emission was directed to a 535/30-nm emission filter. Red fluorescent protein was excited at 570 nm (slit width, 10 nm) via a 585 DCXR dichroic mirror, and in turn emission light was directed to a 620/60-nm emission filter. All image acquisitions were background corrected, and YFP/CFP FRET ratios were bleed-through corrected (55%) for the CFP leakage into the YFP channel.

Live HUVEC morphology change measurements
-----------------------------------------

Transfected HUVECs on glass coverslips were placed in Attofluor cell chambers 16--20 h after transfection. Image collection was performed on the microscope systems as described above. Image analysis was performed in ImageJ; after background subtraction, a smooth filter was used to reduce the noise. Next, a threshold was applied, creating binary images with values of either 255 (signal) or 0 (no signal). Binary images of the prestimulated and stimulated condition were then subtracted by 254 and 253, respectively. These two images were summed, creating image values of 0 (representing the background, displayed in black), 1 (representing contraction, displayed in red), 2 (representing expansion, displayed in blue), and 3 (representing unchanged areas, displayed in white).
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